



EHA2021 abstracts: What's hot in MPN?

To help navigate the exciting content being presented at the EHA2021 Virtual Congress, the MPN Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in MPN, in the following categories: updates in JAK inhibition, novel approaches in treating MPN, overall survival in MF, rare MPN types, and preclinical data.



Sessions to look out for

p202-2	Plenary session	Functional consequences of mutations in MPN	June 12, 2021 2:45 PM – 3:15 PM (CEST)
p103	Education session	Genomics & treatment of MPN <ul style="list-style-type: none">• p103-1: BM niche & milieu• p103-2: Management of toxicity of JAK2 inhibitors• p103-3: Management of PV	Available on-demand Live Q&A session on June 16, 2021 12:00 PM – 12:45 PM (CEST)



JAK inhibition

Abstract	Type	Title
S158	Oral presentation	<u>IMPACT OF RUXOLITINIB ON SURVIVAL OF PATIENTS WITH MYELOFIBROSIS IN REAL WORLD – UPDATE OF ERNEST (EUROPEAN REGISTRY FOR MYELOPROLIFERATIVE NEOPLASMS) STUDY</u>
S202	Oral presentation	<u>TRANSFUSION INDEPENDENCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MYELOFIBROSIS PATIENTS RECEIVING MOMELOTINIB</u>
S203	Oral presentation	<u>OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH FEDRATINIB AS FIRST-LINE MYELOFIBROSIS (MF) THERAPY AND AFTER PRIOR RUXOLITINIB (RUX): RESULTS FROM THE JAKARTA AND JAKARTA2 TRIALS</u>
S204	Oral presentation	<u>JAKTINIB, A NOVAL JAK INHIBITOR IN TREATMENT OF PATIENTS WITH ADVANCED MYELOFIBROSIS: PRELIMINARY RESULTS FROM A PHASE 2 STUDY</u>
EP1079	E-poster	<u>HIGH MOLECULAR RISK MUTATIONS ARE BIOMARKERS OF CLINICAL RESPONSE AND OUTCOME IN INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB</u>
EP1081	E-poster	<u>IMPROVED TRANSFUSION INDEPENDENCE RATES FOR MOMELOTINIB VS RUXOLITINIB IN ANEMIC JAKI NAÏVE MYELOFIBROSIS PATIENTS INDEPENDENT OF BASELINE PLATELET OR TRANSFUSION STATUS</u>
EP1092	E-poster	<u>IMPACT OF BONE MARROW FIBROSIS GRADE ON RESPONSE AND OUTCOME IN PATIENTS WITH PRIMARY MYELOFIBROSIS TREATED WITH RUXOLITINIB: A POST-HOC ANALYSIS OF THE JUMP STUDY</u>

Novel approaches in treating MPN

Abstract	Type	Title
EP1074	E-poster	<u>A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ADVANCED MYELOFIBROSIS</u>
EP1075	E-poster	<u>ADD-ON PARSACLISIB (A PI3K-DELTA INHIBITOR) IN PATIENTS WITH MYELOFIBROSIS AND SUBOPTIMAL RESPONSE TO RUXOLITINIB: INTERIM ANALYSIS FROM A PHASE 2 STUDY</u>
EP1076	E-poster	<u>TOWARDS A POTENTIAL OPERATIONAL CURE IN PATIENTS WITH POLYCYTHAEMIA VERA? RESULTS FROM FIVE YEARS' ROPEGINTERFERON ALPHA-2B THERAPY IN A RANDOMIZED SETTING</u>
EP1077	E-poster	<u>PELABRESIB (CPI-0610) IMPROVED ANEMIA ASSOCIATED WITH MYELOFIBROSIS: INTERIM RESULTS FROM MANIFEST PHASE 2 STUDY</u>
EP1078	E-poster	<u>NAVITOCCLAX AND RUXOLITINIB FOR PATIENTS WITH MYELOFIBROSIS AND JAK INHIBITOR EXPERIENCE: RESPONSE DURATION IN PHASE 2 STUDY</u>
EP1080	E-poster	<u>BET INHIBITOR PELABRESIB DECREASES INFLAMMATORY CYTOKINES, IMPROVES BONE MARROW FIBROSIS AND FUNCTION, AND DEMONSTRATES CLINICAL RESPONSE IRRESPECTIVE OF MUTATION STATUS IN MYELOFIBROSIS PATIENTS</u>
EP1085	E-poster	<u>CLINICAL BENEFIT OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB IN JAK INHIBITOR TREATMENT NAÏVE MYELOFIBROSIS PATIENTS: INTERIM EFFICACY SUBGROUP ANALYSIS FROM ARM 3 OF MANIFEST PH2 STUDY</u>

Novel approaches in treating MPN

Abstract	Type	Title
EP1086	E-poster	<u>A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)</u>
EP1106	E-poster	<u>IMETELSTAT DEMONSTRATES AN ACCEPTABLE SAFETY PROFILE IN MYELOID MALIGNANCIES</u>
S200	Oral presentation	<u>RUSFERTIDE (PTG-300) ELIMINATES THE NEED FOR THERAPEUTIC PHLEBOTOMY IN BOTH LOW AND HIGH-RISK POLYCYTHEMIA VERA (PV) PATIENTS</u>
EP1091	E-poster	<u>ANALYSIS OF THROMBOTIC AND BLEEDING COMPLICATIONS IN 1381 ESSENTIAL THROMBOCYTHEMIA PATIENTS ASSESSED BY R-IPSET THROMBOSIS RISK SCORE: A MULTICENTER RETROSPECTIVE STUDY</u>



Overall Survival in MPN

Abstract	Type	Title
S158	Oral presentation	<u>IMPACT OF RUXOLITINIB ON SURVIVAL OF PATIENTS WITH MYELOFIBROSIS IN REAL WORLD – UPDATE OF ERNEST (EUROPEAN REGISTRY FOR MYELOPROLIFERATIVE NEOPLASMS) STUDY</u>
S203	Oral presentation	<u>OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH FEDRATINIB AS FIRST-LINE MYELOFIBROSIS (MF) THERAPY AND AFTER PRIOR RUXOLITINIB (RUX): RESULTS FROM THE JAKARTA AND JAKARTA2 TRIALS</u>
EP1096	E-poster	<u>OVERALL AND CAUSE SPECIFIC CHANGES IN MORTALITY OF PATIENTS WITH MYELOFIBROSIS OVER THE LAST 3 DECADES</u>

Rare subtypes in MPN

Abstract	Type	Title
S199	Oral presentation	<u>BH3-MIMETICS AND AZACITIDINE SHOW SYNERGISTIC EFFECTS ON JUVENILE MYELOMONOCYTIC LEUKEMIA</u>
S201	Oral presentation	<u>EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY</u>
EP1087	E-poster	<u>SAFETY AND EFFICACY OF MEPOLIZUMAB IN HYPEREOSINOPHILIC SYNDROME: AN OPEN-LABEL EXTENSION STUDY</u>
EP1100	E-poster	<u>MYELOPROLIFERATIVE NEOPLASMS IN PEDIATRICS AND YOUNG ADULTS: GENOMIC FEATURES, CLINICAL OUTCOMES, PROGRESSION AND OVERALL SURVIVAL</u>



Preclinical data

Abstract	Type	Title
S195	Oral presentation	<u>INTERFERON-ALPHA TREATMENT RESULTS IN THE DEPLETION OF DORMANT JAK2-MUTANT HSC IN A MURINE MODEL OF POLYCYTHEMIA VERA</u>
S196	Oral presentation	<u>CALR FRAMESHIFT MUTATIONS ACCELERATE MATURATION OF MEGAKARYOCYTES IN MPN PATIENT-DERIVED IPS CELLS</u>
S197	Oral presentation	<u>TYK2 INHIBITION IS A NOVEL SELECTIVE THERAPEUTIC APPROACH FOR CALR- BUT NOT JAK2V617F-MUTANT MYELOPROLIFERATIVE NEOPLASMS</u>
S198	Oral presentation	<u>IDENTIFICATION AND PHENOTYPIC CHARACTERIZATION OF DISEASE-INITIATING CD34+/CD38- STEM CELLS IN BCR-ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS</u>
EP1057	E-poster	<u>ANTI-TMPRSS6 RNAI THERAPY AS A NOVEL TREATMENT OPTION FOR POLYCYTHAEMIA VERA</u>
EP1058	E-poster	<u>TAMOXIFEN CAN REDUCE MITOCHONDRIAL RESPIRATION, ONCOGENIC JAK-STAT SIGNALING AND MUTANT ALLELE BURDEN IN A SUBSET OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – RESULTS OF THE TAMARIN PHASE II STUDY</u>
EP1063	E-poster	<u>DISTINCT GENE EXPRESSION PROFILES AND MOLECULAR MARKERS IN CD34+ CELLS FROM PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS</u>
EP1065	E-poster	<u>CDK4/CDK6-INHIBITION AS A POTENT APPROACH TO AUGMENT ANTI-NEOPLASTIC EFFECTS OF MIDOSTAURIN, AVAPRITINIB AND NINTEDANIB IN KIT D816V+ NEOPLASTIC MAST CELLS</u>
EP1066	E-poster	<u>TARGETING HDAC AS A NOVEL THERAPEUTIC APPROACH TO COUNTERACT GROWTH OF NEOPLASTIC MAST CELLS IN ADVANCED SYSTEMIC MASTOCYTOSIS</u>



Follow us on Twitter to keep up to
date with the latest from the
EHA2021 Virtual Congress!

@MPN_Hub
#EHA2021
MPN-hub.com